Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer

January 12, 2026 Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer This article was originally published in Life Technology Clinical study in International Journal of Gynecological Cancer shows promising results for platinum-resistant ovarian cancer. Elenagen DNA therapy with gemcitabine benefits women with PROC and high CA-125 levels. Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel DNA-based therapy, Elenagen, administered in combination with the standard chemotherapy gemcitabine in women with PROC and elevated CA-125. The study focused on assessing the efficacy and safety of Elenagen in treating platinum-resistant ovarian cancer, a challenging condition with limited treatment options. Platinum resistance in ovarian cancer often leads to poor prognosis and limited response to standard therapies, making the development of novel treatment approaches crucial. Elenagen, a DNA-based therapy, works by targeting specific genetic pathways involved in cancer progression. By leveraging the unique properties of DNA, Elenagen aims to enhance the body's natural defense mechanisms against cancer cells, potentially overcoming resistance to traditional chemotherapy agents like platinum-based drugs. The combination of Elenagen with gemcitabine represents a promising strategy to improve outcomes for women with platinum-resistant ovarian cancer. Gemcitabine, a commonly used chemotherapy drug, works by interfering with the growth and spread of cancer cells, complementing the targeted approach of Elenagen. The study enrolled a cohort of women with PROC and elevated CA-125 levels, a biomarker often associated with ovarian cancer. Patients received a tailored treatment regimen consisting of Elenagen and gemcitabine, with regular monitoring of treatment response and side effects.

The release as fetched from its publisher. curelaboncology.com ↗